Buswell J F, Barber D M
Br Vet J. 1989 Nov-Dec;145(6):552-7. doi: 10.1016/0007-1935(89)90117-6.
The commercial use of sheep for the production of milk and milk products is attractive to farmers actively diversifying their dairy interests due to the impact of the quota system. As intensification of milking increases, flock sizes will enlarge and the incidence of ovine mastitis will inevitably increase. The pharmaceutical industry and the veterinary practitioner will be required to provide advice and data upon the performance of currently available bovine intramammary preparations for the sheep. This study produces evidence to confirm that one available bovine intramammary preparation, when infused into milking sheep, produced a withholding time approximately three times as long as that defined for the cow. Following a course of three infusions over a period of 24 hours after consecutive milkings, milk was not acceptable for human consumption or for the production of cheese and yoghurts until 136 hours following the final infusion. This situation is likely to be representative of that which will occur with other intramammary products used in the ovine species following infusion with bovine intramammary preparations.
由于配额制度的影响,将绵羊用于商业生产牛奶及奶制品,对那些积极拓展乳制品业务的奶农来说颇具吸引力。随着挤奶强度的增加,羊群规模将会扩大,绵羊乳腺炎的发病率也将不可避免地上升。制药行业和兽医从业者需要就目前可用的牛用乳房内制剂在绵羊身上的使用效果提供建议和数据。本研究提供的证据证实,有一种可用的牛用乳房内制剂在注入挤奶绵羊体内后,其停药期约为牛规定停药期的三倍。在连续挤奶后的24小时内进行三次注入后,直至最后一次注入后的136小时,所产牛奶均不适合人类食用,也不能用于生产奶酪和酸奶。这种情况可能代表了在绵羊身上使用牛用乳房内制剂后,其他乳房内产品也会出现的情况。